Compare EB & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EB | KMDA |
|---|---|---|
| Founded | 2003 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 436.6M | 385.3M |
| IPO Year | 2018 | N/A |
| Metric | EB | KMDA |
|---|---|---|
| Price | $4.47 | $7.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $5.00 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 1.8M | 95.1K |
| Earning Date | 02-26-2026 | 11-10-2025 |
| Dividend Yield | N/A | ★ 2.69% |
| EPS Growth | N/A | ★ 30.41 |
| EPS | N/A | ★ 0.35 |
| Revenue | ★ $294,798,000.00 | $174,787,000.00 |
| Revenue This Year | N/A | $14.79 |
| Revenue Next Year | $4.70 | $10.74 |
| P/E Ratio | ★ N/A | $20.91 |
| Revenue Growth | N/A | ★ 10.36 |
| 52 Week Low | $1.81 | $5.54 |
| 52 Week High | $4.47 | $9.16 |
| Indicator | EB | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 81.66 | 71.72 |
| Support Level | $4.43 | $6.92 |
| Resistance Level | $4.46 | $7.17 |
| Average True Range (ATR) | 0.02 | 0.17 |
| MACD | -0.07 | 0.05 |
| Stochastic Oscillator | 77.78 | 78.33 |
Eventbrite Inc is a self-service ticketing and experience technology platform that serves event creators. The company's two-sided marketplace connects creators and consumers every month to share their passions, artistry, and causes through live experiences. Creators use its self-service ticketing and marketing tools to plan, promote, and sell tickets to their events, and event seekers use its website and mobile application to discover and purchase tickets to experiences. Geographically, it generates maximum revenue from the United States. The company generates revenues principally from service fees and payment processing fees from the sale of paid tickets on its platform.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.